Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Respiratory Tract Diseases AND Thoracic Diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    759 result(s) found for: Respiratory Tract Diseases AND Thoracic Diseases. Displaying page 2 of 38.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-001089-90 Sponsor Protocol Number: OTT329/402 Start Date*: Information not available in EudraCT
    Sponsor Name:Oriel Therapeutics, a Sandoz Company
    Full Title: Study to Test the Product Robustness of a Dry Powder Inhalation Device When Used in Normal Clinical Practice with Young Asthma Patients
    Medical condition: The study is designed to demonstrate the robustness of the OT329 Solis product. The primary endpoint that is derived from the dataset will be product robustness after approximately 21-24 days of ...
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003561 Asthma, unspecified LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-003504-22 Sponsor Protocol Number: UCDCRC/015/006 Start Date*: 2015-10-09
    Sponsor Name:UCD
    Full Title: The NAPRESSIM trial. The use of low dose prophylactic naloxone infusion to prevent respiratory depression with intrathecal morphine.
    Medical condition: Respiratory Depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038678 Respiratory depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003239-76 Sponsor Protocol Number: LAN-BR-11-001 Start Date*: 2012-05-07
    Sponsor Name:BRUSCHETTINI SRL
    Full Title: Efficacy and tolerability clinical trial of Lantigen B (A bacterial lysate having immunostimulating activity) in the prophylaxis of respiratory infections, with special reference to patients with a...
    Medical condition: Episodes classified by upper respiratory infections (otitis, tonsillitis, sinusitis, pharyngotonsillitis, nasopharyngitis) and lower respiratory tract (bronchitis, pneumonia).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10060693 Respiratory tract infection bacterial PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10063527 Allergic respiratory symptom PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005658-20 Sponsor Protocol Number: FGCL-3019-067 Start Date*: 2016-02-23
    Sponsor Name:FibroGen, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients with Idiopathic Pulmonary Fibrosis
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10033979 Parenchymal lung disorders NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-020403-75 Sponsor Protocol Number: ACEmeVent-Pilot Start Date*: 2011-10-24
    Sponsor Name:Universität Leipzig
    Full Title: ACE inhibitor for lung protection during mechanical Ventilation for acute lung injury - pilot trial
    Medical condition: acute lung injury, ALI/ARDS
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10069351 Acute lung injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015875-28 Sponsor Protocol Number: CF002 Start Date*: 2009-10-07
    Sponsor Name:UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: Modulation of intestinal and extraintestinal inflammation in infants with Cystic Fibrosis by early modification of intestinal microflora
    Medical condition: infants with cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017947 SOC
    9.1 10038738 SOC
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000598-95 Sponsor Protocol Number: HS-20-674 Start Date*: 2021-07-30
    Sponsor Name:Camurus AB
    Full Title: A Phase 2, randomized, double-blind, placebo-controlled, multi-center trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acute respiratory distress ...
    Medical condition: Acute respiratory distress syndrome (ARDS) caused by COVID-19 or other disorders
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003449-17 Sponsor Protocol Number: MC/PR/15009/001/11 Start Date*: 2012-05-31
    Sponsor Name:CHIESI
    Full Title: A 12-week, multicenter, randomized, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster NEXThaler (beclomethasone dipropionate 100 µg plus formotero...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002224-20 Sponsor Protocol Number: 29BRC21.0131 Start Date*: 2021-07-09
    Sponsor Name:CHRU de Brest
    Full Title: PET / CT of pulmonary perfusion with Gallium68 for the preservation of pulmonary function during pulmonary stereotaxic radiotherapy.
    Medical condition: Non-small cell lung cancer (NSCLC) or lung metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003901-93 Sponsor Protocol Number: RC2019.1.6_GIAQUINTO Start Date*: 2020-05-27
    Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
    Full Title: Monocentric, indipendent, phase II clinical trial, randomized in open to three different lZ delivery sequences in pediatric patients aged 1 and 12, in intensive care and mechanically ventilated.
    Medical condition: Critical patients subjected to mechanical ventilation and hospitalized in PICU
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004630-14 Sponsor Protocol Number: BFS-AS-40035 Start Date*: 2014-01-23
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 12 Week, Randomized, Open-Label, Parallel Group Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) Spiromax(160/4.5 and 320/9 mcg) as Compared to SYMBICORT® TURBOHA...
    Medical condition: Persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001420-34 Sponsor Protocol Number: 0001 Start Date*: 2020-04-14
    Sponsor Name:Aarhus University
    Full Title: Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency – A Randomized, Open-Label, Phase II Trial
    Medical condition: Infection with COVID19
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-003486-19 Sponsor Protocol Number: 1.002.20 Start Date*: 2020-10-08
    Sponsor Name:University of Dundee
    Full Title: A randomised, double-blind, placebo-controlled trial of SFX-01 or placebo on a backbone of best standard care, to improve outcomes in patients with community acquired pneumonia and suspected or con...
    Medical condition: Community acquired pneumonia with suspected or confirmed SARS-CoV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10066724 Acute pneumonia LLT
    20.1 10021881 - Infections and infestations 10010120 Community acquired pneumonia LLT
    23.0 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-002913-16 Sponsor Protocol Number: 0135-0347 Start Date*: 2020-11-26
    Sponsor Name:SCS Boehringer Ingelheim Comm. V
    Full Title: The TRISTARDS trial - ThRombolysIS Therapy for ARDS A Phase IIb/III operationally seamless, open-label, randomised, sequential, parallel-group adaptive study to evaluate the efficacy and safety of ...
    Medical condition: Acute respiratory distress syndrome caused by Covid-19
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) AT (Ongoing) PT (Completed) NL (Completed) FR (Completed) DK (Prematurely Ended) IT (Prematurely Ended) PL (Completed) RO (Ongoing) ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-001612-25 Sponsor Protocol Number: REP0122 Start Date*: 2022-10-12
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as add-on therapy to standard of care in adult patients with ...
    Medical condition: Acute Respiratory Distress Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000643-33 Sponsor Protocol Number: TFR116341 Start Date*: 2014-08-26
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Placebo Controlled, Double-blind, Multi-centre, Single Dose, Parallel Group, Randomised Clinical Trial of GSK2862277 in Patients undergoing Oesophagectomy Surgery.
    Medical condition: Prevention and treatment of Acute Respiratory Distress Syndrome (ARDS) and other acute inflammatory conditions
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10069351 Acute lung injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005637-11 Sponsor Protocol Number: BV-2007/06 Start Date*: 2008-08-04
    Sponsor Name:OM Pharma SA
    Full Title: Efficacy of Broncho-Vaxom in elderly patients with chronic bronchitis; a double-blind, randomised, placebo-controlled study
    Medical condition: Chronic bronchitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10008841 Chronic bronchitis LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001203-16 Sponsor Protocol Number: LIBERATE Start Date*: 2020-05-06
    Sponsor Name:Guy's and St Thomas' NHS Foundation Trust [...]
    1. Guy's and St Thomas' NHS Foundation Trust
    2. King's College London
    Full Title: Lipid ibuprofen versus standard of care for acute hypoxaemic respiratory failure due to COVID-19: a multicentre, randomised, controlled trial
    Medical condition: COVID-19; respiratory failure; hypoxaemia.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001053 Acute respiratory failure PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021141 Hypoxaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-001308-40 Sponsor Protocol Number: INHIXACOVID19 Start Date*: 2020-05-04
    Sponsor Name:ALMA MATER STUDIORUM UNIVERSITà DI BOLOGNA
    Full Title: Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19
    Medical condition: Hospitalized adult patients with microbiologically confirmed moderate-severe COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016506-17 Sponsor Protocol Number: OXYGEN-TIPO Start Date*: 2010-04-20
    Sponsor Name:U.O. Terapia intensiva
    Full Title: RIGOROUS NORMOXYA MAINTENANCE IN INTENSIVE CARE UNIT: RANDOMIZED CONTROLLED TRIAL.
    Medical condition: Critically ill patients because of chronic or acute respiratory, circulatory, neurologic, infective, metabolic, renal or hepatic pathologies.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038738 SOC
    9.1 10047065 SOC
    9.1 10019805 SOC
    9.1 10021881 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 10:23:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA